Target Technology

Drug Targeting Technology Physical Chemical Biological Methods, edited by Hans Schreier... 

The approval of fhese immunotoxin conjugates demonstrates rather remarkably how this truly targeted technological approach has already shown it can work in at least two clinical situations. 

Beljaars E, Melgert BN, Meijer DKF, Molema G, Poelstra K, In Drug Targeting Technology A Critical Analysis of Physical, Chemical and Biological Methods (Ed. Schreier H). Marcel Dekker Inc., New York, 2001. 

Azhakanandam, K., Weissinger, S.M., Nicholson, J.S., Qu, R and Weissinger, A.K. (2007). Amplicon-plus targeting technology (APTT) for rapid production of a highly unstable vaccine protein in tobacco plants. Plant Mol. Biol. 63 393-404. 

We must identify target technologies that realistically might be replaced by green technologies and to ponder the alternatives. 

Yamada M, Basile AS, Fedorova I, et al. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci. 2003 74 345-353. 

The purpose of this chapter is to provide a general overview and describe some of the fundamentals of advanced dmg delivery and targeting, prior to going into specific detail on advanced dmg delivery and targeting technologies, and specific routes of delivery, in the subsequent chapters. 

In this book, the term dmg delivery system (DDS) is used as a general term to denote any type of advanced delivery system. Conventional dmg delivery systems are simple oral, topical or injection formulations. A DDS, as used here, represents a more sophisticated system which may incorporate one, or a combination, of advanced technologies such as rate-control, pulsatile release or bioresponsive release to achieve spatial and/or temporal delivery. A dmg delivery and targeting system (DDTS) specifically describes an advanced delivery system that incorporates some type of specific targeting technology (such as, for example, monoclonal antibodies) such systems are currently most advanced for use in the parenteral administration of dmgs. Also, rate-control and dmg targeting are treated as two separate issues in this book and are dealt with in detail in Chapters 4 and 5 respectively. 

The concept should be presented in the form of an executive summary. As the first element of evaluation, it is a GO/NO GO criterion. This means that this section of the deliverables must be clearly commimicated for the project to even be considered. The concept is made up of five parts the vision, targeted product(s), targeted technology, targeted market(s), and the intended benefits to the customer. In contrast to the other deliverables, there are no increasing hurdles for this criterion. The concept should, however, be reassessed constantly and may change as the project moves toward commercialization. 

---